Patents by Inventor Arthur W. Nienhuis

Arthur W. Nienhuis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adeno-associated virus capable of expressing factor IX protein and cells comprising the same
    Patent number: 6670176
    Abstract: The subject invention concerns a recombinant adeno-associated virus vector characterized as being capable of delivering and expressing at least one mammalian gene into a genome of a mammalian host cell such that the expression of the gene is regulated in a tissue specific manner by cis-acting regulatory and promoter elements of the gene. A method of using this recombinant adeno-associated virus vector for therapeutic purposes is also provided.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: December 30, 2003
    Assignees: National Institutes of Health, University of Pittsburgh
    Inventors: Richard Jude Samulski, Christopher E. Walsh, Arthur W. Nienhuis, Johnson M. Liu, Jeffrey L. Miller
  • Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
    Patent number: 6268213
    Abstract: The subject invention concerns a recombinant adeno-associated virus vector characterized as being capable of delivering and expressing at least one mammalian gene into a genome of a mammalian host cell such that the expression of the gene is regulated in a tissue specific manner by cis-acting regulatory and promoter elements of the gene. A method of using this recombinant adeno-associated virus vector for therapeutic purposes is also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 31, 2001
    Inventors: Richard Jude Samulski, Christopher E. Walsh, Arthur W. Nienhuis, Johnson M. Liu, Jeffrey L. Miller
  • Recombinant adeno-associated viral vectors
    Patent number: 5780447
    Abstract: The present invention provides a vector comprising an enhancer element and a nuclear matrix association region inserted between an inverted terminal repeat of adeno-associated virus. The vector can further comprise a heterologous nucleic acid inserted into the vector. The present invention further provides a method for integration of a nucleic acid into the genome of a cell, comprising administering to the cell a vector comprising an enhancer element, a heterologous nucleic acid and a nuclear matrix association region, each inserted between an inverted terminal repeat of adeno-associated virus, thereby integrating the nucleic acid into the genome of the cell.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: July 14, 1998
    Assignee: St. Jude Children's Research Hospital
    Inventor: Arthur W. Nienhuis
  • Stable virus packaging cell lines
    Patent number: 5750396
    Abstract: The field of the invention is recombinant packaging and producer cell lines for producing infectious retroviral vectors. The invention more specifically relates to the generation of pseudotyped retroviral vectors with a broad host range which can be produced at high titers in specially constructed packaging cell lines. Most specifically, the invention relates to the generation of pseudotyped retroviral vectors having vesicular stomatitis virus-G protein (VSV-G) as the membrane-associated viral envelope protein.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: May 12, 1998
    Assignees: St. Judes Children's Research Hospital, Genetic Therapy, Inc.
    Inventors: Yanping Yang, Elio F. Vanin, Gerard C. Grosveld, Arthur W. Nienhuis
  • Retroviral vector particles
    Patent number: 5710037
    Abstract: A retroviral vector which includes a nucleic acid sequence encoding a retroviral envelope. The nucleic acid sequence encoding a retroviral envelope includes a first nucleic acid sequence encoding a first envelope portion which is a portion of MCF viral gp 70 protein, a nucleic acid sequence which encodes xenotropic envelope, a nucleic acid sequence which encodes an amphotropic envelope portion, and a nucleic acid sequence which encodes p15E protein. Such retroviral envelopes encoded by such nucleic acid sequence may be included in infectious viral particles. The infectious viral particles also may include gene(s) encoding therapeutic agents, and thus may be used in gene therapy.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: January 20, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elio F. Vanin, Arthur W. Nienhuis